Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a major post-transcriptional regulator of low-density lipoprotein receptor degradation. Recently, PCSK9 was shown to be overexpressed by liver cells in rats with proteinuria. However, the levels of PCSK9 in newly diagnosed primary n...
Main Authors: | Huaying Shen, Sheng Feng, Ying Lu, Linsen Jiang, Tingting Yang, Zhi Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | Renal Failure |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/0886022X.2020.1756846 |
Similar Items
-
Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
by: Jeffrey D. Browning, et al.
Published: (2010-11-01) -
Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
by: Dipti Athavale, et al.
Published: (2018-10-01) -
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
by: Jason S. Troutt, et al.
Published: (2010-02-01) -
Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways
by: Vittoria Cammisotto, et al.
Published: (2021-07-01) -
The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process – is there a link?
by: Malwina Grobelna, et al.
Published: (2019-10-01)